Abstract Background Direct oral anticoagulants (DOACs) are preferred over warfarin for the
treatment of venous thromboembolism (VTE) as well as atrial fibrillation (AF). The efficacy …

Background: Real-world data show limited utilization of direct oral anticoagulants (DOACs)
in obese patients (body mass index [BMI]≥ 30 kg/m2) due to concerns regarding their …

Extreme obesity—also referred to as severe, grade III, or morbid obesity—is defined as a
body mass index (BMI)> 40 kg/m2, and occurs in 7.7% of the adult US population. 1 This …

Background: Limited clinical data exists regarding use of direct oral anticoagulants (DOACs)
in extreme obesity, specifically those≥ 140 kg or having a body mass index (BMI)≥ 50 …

In 2016, the International Society on Thrombosis and Haemostasis (ISTH) published
guidelines advising caution when using direct oral anticoagulants (DOACs) in patients with …

Purpose: There is limited clinical data evaluating anticoagulation with the direct oral
anticoagulants (DOACs) in morbidly obese patients. We sought to examine the efficacy in …

Abstract Background Direct oral anticoagulants (DOACs) are widely used for the treatment of
venous thromboembolism (VTE) and for stroke prevention in atrial fibrillation (AF). However …

Objective: To review literature on the use of direct-acting oral anticoagulants (DOACs) in
patients with high body weight (BW) and/or high body mass index (BMI) and to make …

Despite evolving evidence, the use of direct oral anticoagulants (DOACs) in patients with
extremes of body weight remains controversial. This study aimed to measure the impact of …

Obesity plays an essential role in the safety of pharmacologic drugs. There is paucity of data
for direct oral anticoagulants (DOACs) in the obese, despite these agents becoming more …